Updated Results Announced for ThermoDox Use for HCC

Share this content:
Novel Kinase Inhibitor Shows Efficacy in Patients with Advanced HCC Tumors Overexpressing AFP
Novel Kinase Inhibitor Shows Efficacy in Patients with Advanced HCC Tumors Overexpressing AFP

Celsion announced updated results from its HEAT Study post-hoc analysis which examined the use of ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) for the treatment of hepatocellular carcinoma (HCC), or primary liver cancer. Celsion also released a review of the final study design of the Phase 3 OPTIMA study which will investigate the use of ThermoDox for the same indication.

RELATED: Gastrointestinal Cancers Resource CEnter

As of March 31, 2014, data from the HEAT Study post-hoc analysis demonstrated that ThermoDox may improve overall survival, compared to RFA control, in patients whose lesions undergo RFA treatment for 45 minutes or more. These findings apply to patients with single HCC lesions (64.4% of the HEAT Study population) from both the 3–5cm and 5–7cm cohorts of the HEAT study and represent a subgroup of 285 patients (41%). For this subgroup, clinical results indicate a 50% improvement in overall survival (HR: 0.666; 95% CI 0.434–1.022; p-Value=0.06). The median overall survival for this subgroup has not been met yet.

Celsion anticipates patient enrollment in the OPTIMA Study to begin in mid-2014.

For more information call (609) 896-9100 or visit Celsion.com.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs